CHA2DS2-VASc Score Calculator
Stroke Risk Assessment
Select each clinical characteristic. The score updates automatically.
For patients with atrial fibrillation, assess individual thromboembolic risk and clinical context.
The absolute event rate associated with a given score varies among populations. This score supports, but does not replace, individualized clinical assessment and shared decision-making.
About the CHA₂DS₂-VASc Score
CHA₂DS₂-VASc is a clinical risk score used to estimate thromboembolic risk in patients with atrial fibrillation and to support decisions about oral anticoagulation. The maximum score is 9.
Variables and points
| Component | Definition | Points |
|---|---|---|
| C | Congestive heart failure / LV dysfunction | 1 |
| H | Hypertension | 1 |
| A₂ | Age ≥75 years | 2 |
| D | Diabetes mellitus | 1 |
| S₂ | Prior stroke, TIA, or thromboembolism | 2 |
| V | Vascular disease | 1 |
| A | Age 65–74 years | 1 |
| Sc | Female sex category | 1 |
Interpreting the result
Under the 2023 ACC/AHA/ACCP/HRS guideline, oral anticoagulation is recommended when estimated annual thromboembolic risk is at least 2% (often corresponding to CHA₂DS₂-VASc ≥2 in men or ≥3 in women). It is reasonable to consider anticoagulation at an estimated risk of 1% to less than 2% (often corresponding to a score of 1 in men or 2 in women), using shared decision-making.
The 2024 ESC guideline uses CHA₂DS₂-VA, which excludes sex category: anticoagulation is recommended at a score ≥2 and should be considered at a score of 1. Use the guideline appropriate to your practice setting.
Clinical notes and references
Important limitations
- Do not add both age categories: age ≥75 years scores 2 points and replaces the 65–74-year category.
- Female sex alone does not generally justify anticoagulation in the absence of other stroke risk factors.
- Do not use a single fixed annual stroke percentage for every score; observed event rates differ by cohort and clinical context.
- Antiplatelet therapy is not a substitute for oral anticoagulation for stroke prevention in eligible patients with atrial fibrillation.
- Mechanical heart valves and moderate-to-severe rheumatic mitral stenosis require a separate anticoagulation pathway; this calculator does not select an anticoagulant.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.